Latest News
Novartis Releases Winter SMA Community Update Letter
Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with SMA, offering a one-time gene […]
Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Biogen Announces Results from the Phase 2/3 DEVOTE Study
Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living […]
SMA Community Research and Legislative Priorities Finalized in New Federal Law
On February 3rd, Congress approved and the President signed into law key research and legislative priorities that Cure SMA and individuals with spinal muscular atrophy (SMA) and their families have […]